Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Typ-2-Diabetes und Adipositas Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Häufige urologisch-sexualmedizinische Themen in der Praxis sind das Thema des MMW-Webinars am 5. Juni von 17.30 bis 19 Uhr. Konkret geht es um die Frage, wann bei Harnwegsinfektionen auf Antibiotika verzichtet werden kann, und um ein Update zur Therapie von Libido- und Potenzstörungen des Mannes. Der dritte Vortrag behandelt sexuell übertragbare Krankheiten. Stellen Sie Ihre Fragen an die Experten und sammeln Sie 2 CME-Punkte. Jetzt gleich anmelden!
Erweiterte Suche
Anmelden
nach oben
Arthritis Research & Therapy
Erschienen in: Arthritis Research & Therapy 6/2011

01.12.2011 | Review

Type I interferon pathway in adult and juvenile dermatomyositis

verfasst von: Emily C Baechler, Hatice Bilgic, Ann M Reed

Erschienen in: Arthritis Research & Therapy | Ausgabe 6/2011

Einloggen, um Zugang zu erhalten

Abstract

Gene expression profiling and protein studies of the type I interferon pathway have revealed important insights into the disease process in adult and juvenile dermatomyositis. The most prominent and consistent feature has been a characteristic whole blood gene signature indicating upregulation of the type I interferon pathway. Upregulation of the type I interferon protein signature has added additional markers of disease activity and insight into the pathogenesis of the disease.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Baechler EC, Batliwalla FM, Reed AM, Peterson EJ, Gaffney PM, Moser KL, Gregersen PK, Behrens TW: Gene expression profiling in human autoimmunity. Immunol Rev. 2006, 210: 120-137. 10.1111/j.0105-2896.2006.00367.x.CrossRefPubMed
2.
Takaoka A, Yanai H: Interferon signalling network in innate defence. Cell Microbiol. 2006, 8: 907-922. 10.1111/j.1462-5822.2006.00716.x.CrossRefPubMed
3.
Reed AM, Stirling JD: Association of the HLA-DQA1*0501 allele in multiple racial groups with juvenile dermatomyositis. Hum Immunol. 1995, 44: 131-135.CrossRefPubMed
4.
Tezak Z, Hoffman EP, Lutz JL, Fedczyna TO, Stephan D, Bremer EG, Krasnoselska-Riz I, Kumar A, Pachman LM: Gene expression profiling in DQA1*0501+ children with untreated dermatomyositis: a novel model of pathogenesis. J Immunol. 2002, 168: 4154-4163.CrossRefPubMed
5.
Chen YW, Shi R, Geraci N, Shrestha S, Gordish-Dressman H, Pachman LM: Duration of chronic inflammation alters gene expression in muscle from untreated girls with juvenile dermatomyositis. BMC Immunol. 2008, 9: 43-10.1186/1471-2172-9-43.PubMedCentralCrossRefPubMed
6.
Zhou X, Dimachkie MM, Xiong M, Tan FK, Arnett FC: cDNA microarrays reveal distinct gene expression clusters in idiopathic inflamatory myopathies. Med Sci Monit. 2004, 10: BR191-BR197.PubMed
7.
Greenberg SA, Pinkus JL, Pinkus GS, Burleson T, Sanoudou D, Tawil R, Barohn RJ, Saperstein DS, Briemberg HR, Ericsson M, Park P, Amato AA: Interferonalpha/beta-mediated innate immune mechanisms in dermatomyositis. Ann Neurol. 2005, 57: 664-678. 10.1002/ana.20464.CrossRefPubMed
8.
Salajegheh M, Kong SW, Pinkus JL, Walsh RJ, Liao A, Nazareno R, Amato AA, Krastins B, Morehouse C, Higgs BW, Jallal B, Yao Y, Sarracino DA, Parker KC, Greenberg SA: Interferon-stimulated gene 15 (ISG15) conjugates proteins in dermatomyositis muscle with perifascicular atrophy. Ann Neurol. 2010, 67: 53-63. 10.1002/ana.21805.PubMedCentralCrossRefPubMed
9.
Raju R, Dalakas MC: Gene expression profile in the muscles of patients with inflammatory myopathies: effect of therapy with IVIg and biological validation of clinically relevant genes. Brain. 2005, 128 (Pt 8): 1887-1896.CrossRefPubMed
10.
De Paepe B, Creus KK, De Bleecker JL: Chemokine profile of different inflammatory myopathies reflects humoral versus cytotoxic immune responses. Ann N Y Acad Sci. 2007, 1109: 441-453. 10.1196/annals.1398.050.CrossRefPubMed
11.
Lopez de Padilla CM, Vallejo AN, McNallan KT, Vehe R, Smith SA, Dietz AB, Vuk-Pavlovic S, Reed AM: Plasmacytoid dendritic cells in inflamed muscle of patients with juvenile dermatomyositis. Arthritis Rheum. 2007, 56: 1658-1668. 10.1002/art.22558.CrossRefPubMed
12.
Caproni M, Torchia D, Cardinali C, Volpi W, Del Bianco E, D'Agata A, Fabbri P: Infiltrating cells, related cytokines and chemokine receptors in lesional skin of patients with dermatomyositis. Br J Dermatol. 2004, 151: 784-791. 10.1111/j.1365-2133.2004.06144.x.CrossRefPubMed
13.
Wenzel J, Schmidt R, Proelss J, Zahn S, Bieber T, Tuting T: Type I interferonassociated skin recruitment of CXCR3+ lymphocytes in dermatomyositis. Clin Exp Dermatol. 2006, 31: 576-582. 10.1111/j.1365-2230.2006.02150.x.CrossRefPubMed
14.
Wenzel J, Worenkamper E, Freutel S, Henze S, Haller O, Bieber T, Tuting T: Enhanced type I interferon signalling promotes Th1-biased inflammation in cutaneous lupus erythematosus. J Pathol. 2005, 205: 435-442. 10.1002/path.1721.CrossRefPubMed
15.
Shrestha S, Wershil B, Sarwark JF, Niewold TB, Philipp T, Pachman LM: Lesional and nonlesional skin from patients with untreated juvenile dermatomyositis displays increased numbers of mast cells and mature plasmacytoid dendritic cells. Arthritis Rheum. 2010, 62: 2813-2822. 10.1002/art.27529.PubMedCentralCrossRefPubMed
16.
O'Connor KA, Abbott KA, Sabin B, Kuroda M, Pachman LM: MxA gene expression in juvenile dermatomyositis peripheral blood mononuclear cells: association with muscle involvement. Clin Immunol. 2006, 120: 319-325. 10.1016/j.clim.2006.05.011.PubMedCentralCrossRefPubMed
17.
Adams EM, Kirkley J, Eidelman G, Dohlman J, Plotz PH: The predominance of beta (CC) chemokine transcripts in idiopathic inflammatory muscle diseases. Proc Assoc Am Phys. 1997, 109: 275-285.PubMed
18.
Civatte M, Bartoli C, Schleinitz N, Chetaille B, Pellissier JF, Figarella-Branger D: Expression of the beta chemokines CCL3, CCL4, CCL5 and their receptors in idiopathic inflammatory myopathies. Neuropathol Appl Neurobiol. 2005, 31: 70-79. 10.1111/j.1365-2990.2004.00591.x.CrossRefPubMed
19.
Confalonieri P, Bernasconi P, Megna P, Galbiati S, Cornelio F, Mantegazza R: Increased expression of beta-chemokines in muscle of patients with inflammatory myopathies. J Neuropathol Exp Neurol. 2000, 59: 164-169.PubMed
20.
De Bleecker JL, De Paepe B, Vanwalleghem IE, Schroder JM: Differential expression of chemokines in inflammatory myopathies. Neurology. 2002, 58: 1779-1785.CrossRefPubMed
21.
Liprandi A, Bartoli C, Figarella-Branger D, Pellissier JF, Lepidi H: Local expression of monocyte chemoattractant protein-1 (MCP-1) in idiopathic inflammatory myopathies. Acta Neuropathol. 1999, 97: 642-648. 10.1007/s004010051041.CrossRefPubMed
22.
De Rossi M, Bernasconi P, Baggi F, de Waal Malefyt R, Mantegazza R: Cytokines and chemokines are both expressed by human myoblasts: possible relevance for the immune pathogenesis of muscle inflammation. Int Immunol. 2000, 12: 1329-1335. 10.1093/intimm/12.9.1329.CrossRefPubMed
23.
Baechler EC, Bauer JW, Slattery CA, Ortmann WA, Espe KJ, Novitzke J, Ytterberg SR, Gregersen PK, Behrens TW, Reed AM: An interferon signature in the peripheral blood of dermatomyositis patients is associated with disease activity. Mol Med. 2007, 13: 59-68.PubMedCentralCrossRefPubMed
24.
Walsh RJ, Kong SW, Yao Y, Jallal B, Kiener PA, Pinkus JL, Beggs AH, Amato AA, Greenberg SA: Type I interferon-inducible gene expression in blood is present and reflects disease activity in dermatomyositis and polymyositis. Arthritis Rheum. 2007, 56: 3784-3792. 10.1002/art.22928.PubMedCentralCrossRefPubMed
25.
Bilgic H, Ytterberg SR, Amin S, McNallan KT, Wilson JC, Koeuth T, Ellingson S, Newman B, Bauer JW, Peterson EJ, Baechler EC, Reed AM: Interleukin-6 and type I interferon-regulated genes and chemokines mark disease activity in dermatomyositis. Arthritis Rheum. 2009, 60: 3436-3446. 10.1002/art.24936.CrossRefPubMed
26.
Liao AP, Salajegheh M, Nazareno R, Kagan JC, Jubin RG, Greenberg SA: Interferon beta is associated with type 1 interferon-inducible gene expression in dermatomyositis. Ann Rheum Dis. 2011, 70: 831-836. 10.1136/ard.2010.139949.CrossRefPubMed
27.
Niewold TB, Kariuki SN, Morgan GA, Shrestha S, Pachman LM: Elevated serum interferon-alpha activity in juvenile dermatomyositis: associations with disease activity at diagnosis and after thirty-six months of therapy. Arthritis Rheum. 2009, 60: 1815-1824. 10.1002/art.24555.PubMedCentralCrossRefPubMed
28.
Niewold TB, Kariuki SN, Morgan GA, Shrestha S, Pachman LM: Gene-gene-sex interaction in cytokine gene polymorphisms revealed by serum interferon alpha phenotype in juvenile dermatomyositis. J Pediatr. 2010, 157: 653-657. 10.1016/j.jpeds.2010.04.034.PubMedCentralCrossRefPubMed
29.
Baechler EC, Batliwalla FM, Karypis G, Gaffney PM, Ortmann WA, Espe KJ, Shark KB, Grande WJ, Hughes KM, Kapur V, Gregersen PK, Behrens TW: Interferon-inducible gene expression signature in peripheral blood cells of patients with severe lupus. Proc Natl Acad Sci USA. 2003, 100: 2610-2615. 10.1073/pnas.0337679100.PubMedCentralCrossRefPubMed
30.
Han GM, Chen SL, Shen N, Ye S, Bao CD, Gu YY: Analysis of gene expression profiles in human systemic lupus erythematosus using oligonucleotide microarray. Genes Immun. 2003, 4: 177-186. 10.1038/sj.gene.6363966.CrossRefPubMed
31.
Bennett L, Palucka AK, Arce E, Cantrell V, Borvak J, Banchereau J, Pascual V: Interferon and granulopoiesis signatures in systemic lupus erythematosus blood. J Exp Med. 2003, 197: 711-723. 10.1084/jem.20021553.PubMedCentralCrossRefPubMed
32.
Ye S, Pang H, Gu YY, Hua J, Chen XG, Bao CD, Wang Y, Zhang W, Qian J, Tsao BP, Hahn BH, Chen SL, Rao ZH, Shen N: Protein interaction for an interferoninducible systemic lupus associated gene, IFIT1. Rheumatology (Oxford). 2003, 42: 1155-1163. 10.1093/rheumatology/keg315.CrossRef
33.
Niewold TB, Wu SC, Smith M, Morgan GA, Pachman LM: Familial aggregation of autoimmune disease in juvenile dermatomyositis. Pediatrics. 2011, 127: e1239-e1246. 10.1542/peds.2010-3022.PubMedCentralCrossRefPubMed
34.
Kim GT, Cho ML, Park YE, Yoo WH, Kim JH, Oh HJ, Kim DS, Baek SH, Lee SH, Lee JH, Kim HY, Kim SI: Expression of TLR2, TLR4, and TLR9 in dermatomyositis and polymyositis. Clinical Rheumatol. 2010, 29: 273-279. 10.1007/s10067-009-1316-7.CrossRef
35.
Horton CG, Pan ZJ, Farris AD: Targeting Toll-like receptors for treatment of SLE. Mediators Inflamm. 2010.
36.
Cappelletti C, Baggi F, Zolezzi F, Biancolini D, Beretta O, Severa M, Coccia EM, Confalonieri P, Morandi L, Mora M, Mantegazza R, Bernasconi P: Type I interferon and Toll-like receptor expression characterizes inflamatory myopathies. Neurology. 2011, 76: 2079-2088. 10.1212/WNL.0b013e31821f440a.CrossRefPubMed
37.
Gunawardena H, Betteridge ZE, McHugh NJ: Myositis-specific autoantibodies: their clinical and pathogenic significance in disease expression. Rheumatology. 2009, 48: 607-612. 10.1093/rheumatology/kep078.CrossRefPubMed
38.
Eloranta ML, Barbasso Helmers S, Ulfgren AK, Ronnblom L, Alm GV, Lundberg IE: A possible mechanism for endogenous activation of the type I interferon system in myositis patients with anti-Jo-1 or anti-Ro 52/anti-Ro 60 autoantibodies. Arthritis Rheum. 2007, 56: 3112-3124. 10.1002/art.22860.CrossRefPubMed
39.
Targoff IN, Reichlin M: The association between Mi-2 antibodies and dermatomyositis. Arthritis Rheum. 1985, 28: 796-803. 10.1002/art.1780280711.CrossRefPubMed
40.
Wang HB, Zhang Y: Mi2, an auto-antigen for dermatomyositis, is an ATP-dependent nucleosome remodeling factor. Nucleic Acids Res. 2001, 29: 2517-2521. 10.1093/nar/29.12.2517.PubMedCentralCrossRefPubMed
41.
Targoff IN, Mamyrova G, Trieu EP, Perurena O, Koneru B, O'Hanlon TP, Miller FW, Rider LG: A novel autoantibody to a 155-kd protein is associated with dermatomyositis. Arthritis Rheum. 2006, 54: 3682-3689. 10.1002/art.22164.CrossRefPubMed
42.
Targoff IN, Trieu EP, Levy-Neto M, Prasertsuntarsai T, Miller FW: Autoantibodies to transcriptional intermediary factor 1-gamma (TIF1-γ) in dermatomyositis [abstract]. Arthritis Rheum. 2006, 54: S518-CrossRef
43.
Oddis CV, Fertig N, Goel A, Espada G, Confalone Gregorian M, Maldonado Cocco MA: Clinical and serological characterisation of the anti-MJ antibody in childhood myositis [abstract]. Arthritis Rheum. 1997, 40: S139-
44.
Kimura Y, Sakai F, Nakano O, Kisaki O, Sugimoto H, Sawamura T, Sadano H, Osumi T: The newly identified human nuclear protein NXP-2 possesses three distinct domains, the nuclear matrix-binding, RNA-binding, and coiled-coil domains. J Biol Chem. 2002, 277: 20611-20617. 10.1074/jbc.M201440200.CrossRefPubMed
45.
Gunawardena H, Wedderburn LR, Chinoy H, Betteridge ZE, North J, Ollier WE, Cooper RG, Oddis CV, Ramanan AV, Davidson JE, McHugh NJ: Autoantibodies to a p140 protein in juvenile dermatomyositis are associated with calcinosis. Arthritis Rheum. 2009, 60: 1807-1814. 10.1002/art.24547.PubMedCentralCrossRefPubMed
46.
Krol P, Krystufkova O, Polanska M, Mann H, Klein M, Beran O, Vencovsky J: Serum levels of interferon α do not correlate with disease activity in patients with dermatomyositis/polymyositis. Ann Rheum Dis. 2011, 70: 879-880. 10.1136/ard.2010.141051.CrossRefPubMed
Metadaten
Titel
Type I interferon pathway in adult and juvenile dermatomyositis
verfasst von
Emily C Baechler
Hatice Bilgic
Ann M Reed
Publikationsdatum
01.12.2011
Verlag
BioMed Central
Erschienen in
Arthritis Research & Therapy / Ausgabe 6/2011
Elektronische ISSN: 1478-6362
DOI
https://doi.org/10.1186/ar3531

Weitere Artikel der Ausgabe 6/2011

Arthritis Research & Therapy 6/2011 Zur Ausgabe

Research article

Mutations in genes encoding complement inhibitors CD46 and CFH affect the age at nephritis onset in patients with systemic lupus erythematosus

Research article

Follistatin-like protein 1: a serum biochemical marker reflecting the severity of joint damage in patients with osteoarthritis

Research article

Plasma proteomic profiles from disease-discordant monozygotic twins suggest that molecular pathways are shared in multiple systemic autoimmune diseases*

Research article

Frequency of Th17 CD20+ cells in the peripheral blood of rheumatoid arthritis patients is higher compared to healthy subjects

Editorial

Multiplex, megaplex, index, and complex: the present and future of laboratory diagnostics in rheumatology

Research article

Effects of Wnt3A and mechanical load on cartilage chondrocyte homeostasis

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

29.05.2024 Larynxkarzinom Nachrichten

Fast ein Viertel der Personen mit mäßig dysplastischen Stimmlippenläsionen entwickelt einen Kehlkopftumor. Solche Personen benötigen daher eine besonders enge ärztliche Überwachung.

Nach Herzinfarkt mit Typ-1-Diabetes schlechtere Karten als mit Typ 2?

29.05.2024 Herzinfarkt Nachrichten

Bei Menschen mit Typ-2-Diabetes sind die Chancen, einen Myokardinfarkt zu überleben, in den letzten 15 Jahren deutlich gestiegen – nicht jedoch bei Betroffenen mit Typ 1.

15% bedauern gewählte Blasenkrebs-Therapie

29.05.2024 Urothelkarzinom Nachrichten

Ob Patienten und Patientinnen mit neu diagnostiziertem Blasenkrebs ein Jahr später Bedauern über die Therapieentscheidung empfinden, wird einer Studie aus England zufolge von der Radikalität und dem Erfolg des Eingriffs beeinflusst.

Costims – das nächste heiße Ding in der Krebstherapie?

28.05.2024 Onkologische Immuntherapie Nachrichten

„Kalte“ Tumoren werden heiß – CD28-kostimulatorische Antikörper sollen dies ermöglichen. Am besten könnten diese in Kombination mit BiTEs und Checkpointhemmern wirken. Erste klinische Studien laufen bereits.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise